BASEL, Switzerland, October 29 /PRNewswire/ -- A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly ...

-- First Publication of Phase III Data in the Clinical Journal of the American Society of Nephrology Results from a multi-centre renal anaemia study show that switching patients directly from frequent ...

being a common adverse event and a burden for patients with chronic kidney disease (CKD).

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anaemia associated with chronic kidney ...

three times a week for the maintenance treatment of anaemia. The study results showed: - Minute changes in patients' haemoglobin (Hb) levels from baseline to evaluation (-0.131g/dL for MIRCERA once ...

The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...